Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Havel's Incorporated Expands Successful EchoStim(R) Ultrasound Needles Into Canada
Havel"s Incorporated, a Cincinnati-based distributor of unique needle devices, has partnered with CHS, Canadian Hospital Specialties, which will become the exclusive distributor of Havel"s EchoStim(R) and EchoBlock(R) Ultrasound Needles throughout Canada.
generic viagra online
Adolescent Obesity Study
Drs. Timothy Halliday and Sally Kwak, economics professors at the University of Hawaii at Manoa, recently published a paper in Economics and Human Biology titled, "Weight Gain in Adolescents and Their Peers." The article examines trends in adolescent body mass index (BMI) in a nationally representative dataset.
News of the day
Squid 'Sight' Shedding Light On Symbiosis Affecting Humans
It"s hard to miss the huge eye of a squid. But now it appears that certain squids can detect light through an organ other than their eyes as well.
Sexual Health

Cellceutix Files Patent Application For Its Cancer Compound

Cellceutix Corporation (OTCBB: CTIX), announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin™ and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates. The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing. George Evans, CEO stated: "This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market. Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures. The result is a patent with new and expanded claims that will provide a strong intellectual property base for Kevetrin and a large portfolio of possible compounds for future development. In the meantime, we"ve been doing some very interesting experiments with Kevetrin and with our psoriasis candidate, KM-133. We anticipate announcing study results over the coming weeks." Cellceutix


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009